GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (NAS:VKTX) » Definitions » Cyclically Adjusted PB Ratio

VKTX (Viking Therapeutics) Cyclically Adjusted PB Ratio : 7.83 (As of May. 28, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Viking Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-05-28), Viking Therapeutics's current share price is $27.18. Viking Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $3.47. Viking Therapeutics's Cyclically Adjusted PB Ratio for today is 7.83.

The historical rank and industry rank for Viking Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

VKTX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 7.84
Current: 7.84

During the past years, Viking Therapeutics's highest Cyclically Adjusted PB Ratio was 7.84. The lowest was 0.00. And the median was 0.00.

VKTX's Cyclically Adjusted PB Ratio is ranked worse than
86.85% of 669 companies
in the Biotechnology industry
Industry Median: 1.49 vs VKTX: 7.84

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Viking Therapeutics's adjusted book value per share data for the three months ended in Mar. 2025 was $7.542. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.47 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Viking Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Viking Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viking Therapeutics Cyclically Adjusted PB Ratio Chart

Viking Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 5.38 9.11 12.83

Viking Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.65 19.57 22.17 12.83 6.96

Competitive Comparison of Viking Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Viking Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viking Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Viking Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Viking Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=27.18/3.47
=7.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viking Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Viking Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=7.542/134.9266*134.9266
=7.542

Current CPI (Mar. 2025) = 134.9266.

Viking Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 1.778 100.684 2.383
201509 1.357 100.392 1.824
201512 0.901 99.792 1.218
201603 0.596 100.470 0.800
201606 0.663 101.688 0.880
201609 0.514 101.861 0.681
201612 0.386 101.863 0.511
201703 0.315 102.862 0.413
201706 0.238 103.349 0.311
201709 0.078 104.136 0.101
201712 0.376 104.011 0.488
201803 1.426 105.290 1.827
201806 2.314 106.317 2.937
201809 4.237 106.507 5.368
201812 4.150 105.998 5.283
201903 4.090 107.251 5.145
201906 3.995 108.070 4.988
201909 3.923 108.329 4.886
201912 3.827 108.420 4.763
202003 3.697 108.902 4.581
202006 3.600 108.767 4.466
202009 3.480 109.815 4.276
202012 3.337 109.897 4.097
202103 3.074 111.754 3.711
202106 2.877 114.631 3.386
202109 2.724 115.734 3.176
202112 2.580 117.630 2.959
202203 2.356 121.301 2.621
202206 2.155 125.017 2.326
202209 1.973 125.227 2.126
202212 1.857 125.222 2.001
202303 1.690 127.348 1.791
202306 3.860 128.729 4.046
202309 3.681 129.860 3.825
202312 3.480 129.419 3.628
202403 8.472 131.776 8.675
202406 8.312 132.554 8.461
202409 8.179 133.029 8.296
202412 7.890 133.157 7.995
202503 7.542 134.927 7.542

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Viking Therapeutics  (NAS:VKTX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Viking Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Viking Therapeutics Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Executives
Sarah Kathryn Rouan director 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
Brian Lian director, officer: President & CEO C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Greg Zante officer: Chief Financial Officer C/O SANGAMO BIOSCIENCES, INC STE-A-100, POINT RICHMOND TECH, 501 CANAL BLVD,, RICHMOND CA 94804
Marianna Mancini officer: Chief Operating Officer C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, STE 250, SAN DIEGO CA 92130
Lawson Macartney director C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
J Matthew Singleton director 286 STANWICH ROAD, GREENWICH CT 06830
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Matthew W Foehr director 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Ligand Pharmaceuticals Inc 10 percent owner 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Hiroko Masamune officer: Chief Development Officer C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Michael Morneau officer: Chief Financial Officer C/O TRIUS THERAPEUTICS, INC., 6410 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Stephen W Webster director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Rochelle Hanley officer: Chief Medical Officer C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037
Michael Dinerman officer: Chief Operating Officer C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037